🔗 Permalink

Inventor profile of:

John Byrd

City:

Columbus, Ohio

Country:

United States

Published Applications:

Last publication date:

2026-03-19

Top Assignees for applications by John Byrd

The entities that hold a legal rights for patent applications filed by inventor Byrd John:

AVENTIS PHARMACEUTICALS INC. 2 Bridgewater, NJ United States
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2 PHILADELPHIA, PA United States
NOVARTIS AG 2 Basel, Switzerland
OHIO STATE UNIVERSITY RESEARCH FOUNDATION 2 COLUMBUS, OH United States
Ohio State Innovation Foundation 1 Columbus, OH United States

Recent patent applications by Byrd John

John Byrd from Columbus, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-03-19

US20260077027A1

Human necessities

PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES

#2 | 2026-02-26

US20260053906A1

Human necessities

DNA ORIGAMI VACCINES

#3 | 2021-06-03

US20210162065A1

Human necessities

MULTI-FUNCTIONAL CANCER DRUG DELIVERY NANODEVICE FOR PRECISION MEDICINE

#4 | 2019-12-26

US20190388471A1

Human necessities

TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

#5 | 2018-07-26

US20180208993A1

Chemistry; metallurgy

HIGHLY SENSITIVE METHODS FOR DETECTING BTK RESISTANCE MUTATIONS IN RNA AND DNA

#6 | 2018-05-24

US20180140602A1

Human necessities

COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES

#7 | 2018-02-08

US20180037653A1

Chemistry; metallurgy

TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

#8 | 2017-10-19

US20170298446A1

Chemistry; metallurgy

BIOMARKERS OF BRUTON TYROSINE KINASE INHIBITOR RESISTANCE

#9 | 2017-05-18

US20170137516A1

Chemistry; metallurgy

TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

#10 | 2015-10-08

US20150283178A1

Human necessities

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

#11 | 2011-10-13

US20110251240A1

Human necessities

Dosing Regimen of Flavopiridol for Treating Cancer

#12 | 2008-01-31

US20080027105A1

Human necessities

Dosing Regimen of Flavopiridol for Treating Cancer`

#13 | 2005-09-01

US20050191632A1

Chemistry; metallurgy

Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia

InventorID:

1312061 ⎘